The Alzheimer's Silence: 90% of Women Want Testing Doctors Aren't Offering

RED BANK, N.J. – June 30, 2026 – In exam rooms across the country, a critical conversation is not happening. A new national survey reveals a stark and dangerous disconnect: while nine out of ten women in midlife are open to early testing for Alzheimer's disease, only a tiny fraction—a mere 9%—report their healthcare providers have ever discussed cognitive health with them. This isn't just a communication gap; it's a systemic failure with profound consequences for the millions of women who are disproportionately affected by the devastating neurological disease.

The findings, from a Harris Poll survey conducted on behalf of the nonprofit HealthyWomen, paint a picture of a patient population that is far more proactive and prepared than the medical establishment gives them credit for. Presented at the American Association for Nurse Practitioners (AANP) National Conference, the data exposes a system where women's concerns about their own brain health are being met with a deafening silence. With 91% of women agreeing that cognitive screening should be as routine as a mammogram or cholesterol test, the question isn't whether patients are ready. The question is, why isn't healthcare?

A System Unprepared for a Ready Public

The urgency is not abstract. One in four women surveyed, all between the ages of 45 and 64, reported they have already noticed changes in their memory or thinking. One in three have a family history of Alzheimer's or dementia. Yet, despite these personal risk factors, the majority feel left in the dark. Half of the women surveyed do not feel knowledgeable about their personal risk, and a staggering two-thirds are unaware of a fundamental fact: women are more likely than men to develop Alzheimer's, accounting for nearly two-thirds of all cases.

"For too long, conversations about Alzheimer's have been shaped by stigma and fear," said Beth Battaglino, RN-C, CEO of HealthyWomen, in a statement accompanying the release. "This survey tells us that women are ready and in need of a different conversation with their providers. They want to be made aware of risks and understand early detection to make informed decisions about their brain health."

The reasons for this disconnect are woven into the fabric of our healthcare system. Primary care providers, constrained by short appointment times and a long list of required screenings, may not have the time or training to initiate sensitive, nuanced conversations about cognitive decline. Furthermore, the lack of clear, universal guidelines for cognitive screening in asymptomatic midlife women—unlike the well-established protocols for breast cancer or heart disease—leaves it in a clinical gray area. Until recently, a sense of therapeutic nihilism, the belief that little could be done for Alzheimer's, also contributed to a lack of urgency around early diagnosis.

The Dawn of a New Diagnostic Era

That clinical reality, however, is rapidly changing, which makes the current silence all the more troubling. The survey was conducted at a pivotal moment in Alzheimer's research, marked by the arrival of FDA-cleared blood biomarker tests. These simple blood draws represent a paradigm shift, offering a less invasive, more accessible, and more affordable way to detect the pathological hallmarks of Alzheimer's—namely amyloid plaques and tau tangles—years before severe symptoms arise.

These tests are not a standalone diagnosis. Rather, they are a powerful tool to assess risk and determine who might benefit from more definitive but costly and invasive procedures like PET scans or cerebrospinal fluid analysis. For the first time, a scalable method for early detection is within reach. Yet, the survey found that only 13% of midlife women are even familiar with them. The innovation is in the lab, but it has not yet reached the patient.

"We are moving from an era of diagnosing Alzheimer's based on symptoms to one where we can identify the underlying biology of the disease," one neurologist not involved in the survey explained. "These blood tests are a crucial first step. They can help us identify the right patients for new treatments and clinical trials when they can be most effective. To not be having these conversations, especially with a high-risk population that is clearly asking for them, is a profound missed opportunity."

From Knowledge to Action: Why Early Detection Matters

The survey makes it clear what motivates women to act. Two-thirds said they would be more likely to pursue testing if they knew that lifestyle changes and medications existed that could slow the disease's progression. This is the crucial link that is often missing from the public discourse: early diagnosis is not about receiving a hopeless fate; it's about opening a window for intervention.

A growing body of evidence from institutions like the Alzheimer's Association and the National Institute on Aging shows that up to 40% of dementia cases may be preventable or delayed through lifestyle modifications. These include regular physical activity, adhering to a brain-healthy diet like the MIND or Mediterranean diet, maintaining social connections, and managing chronic conditions like hypertension and diabetes. Early awareness provides the impetus to adopt these changes when the brain is most resilient.

Furthermore, the pharmaceutical landscape is no longer barren. New disease-modifying therapies, such as Lecanemab, are the first to be approved that target the underlying amyloid plaques and have been shown to modestly slow cognitive and functional decline. The critical caveat is that these drugs are most effective in the early stages of the disease. Without early and accurate detection, patients will miss the window in which these treatments can provide the most benefit.

Demanding the Conversation

The path forward requires a two-pronged approach: empowering patients and educating providers. Advocacy groups like the Women's Alzheimer's Movement and UsAgainstAlzheimer's are already working to raise awareness and fund research into the sex-based differences in the disease. Simultaneously, resources like the AANP's Cognitive Health Point-of-Care tool and the AAFP's Cognitive Care Kit are being developed to equip providers to have these conversations effectively.

Ultimately, the change may need to be driven by the very women the system is currently failing. The survey's most powerful statistic may be this: 90% of women say a provider's recommendation would make them more likely to pursue testing. The data shows women are ready and willing to take that step. Now armed with the knowledge that early detection is possible and that interventions exist, the onus may fall on them to walk into the exam room and transform the silence into a demand for action.